Top
image credit: Unsplash

ISA Pharmaceuticals announce new trial testing technology for cancers

April 14, 2022

A clinical trial of Amplivant – an adjuvant technology to boost immune response to cancer therapy –has started. ISA Pharmaceuticals’ novel technology is being tested in a multicentre clinical trial which is also testing the Moditop vaccine, Modi-1.

The first-in-human clinical trial brings Modi-1 to patients with triple negative breast cancer, ovarian cancer, head and neck cancer and renal cancer using the Amplivant adjuvant technology to boost immune response to the therapy.

Read More on Pharma Times